{
  "cells": [
    {
      "cell_type": "raw",
      "metadata": {},
      "source": [
        "---\n",
        "title: \"Interpreting evidence from real world data\"\n",
        "title-slide-attributes:\n",
        "  data-background-image: hmri_title.png\n",
        "  data-background-size: contain\n",
        "author: \"A/Prof Chris Oldmeadow\"\n",
        "format:\n",
        "  revealjs:\n",
        "    logo: \"HMRILogo_black_wide.png\"\n",
        "    css: \"custom.css.css\"\n",
        "\n",
        "---"
      ],
      "id": "2f0731cb"
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "## Presentation overview\n",
        "\n",
        "-   The RCT and Problems with RCT\n",
        "-   Real World evidence\n",
        "-   Causal modelling with observational data\n",
        "-   The target trial framework\n",
        "-   Touch on some statistical concepts (propensity matching)\n",
        "\n",
        "## The RCT\n",
        "\n",
        "::: columns\n",
        "::: {.column width=\"60%\"}\n",
        "Problems:\n",
        "\n",
        "-   Expensive\n",
        "-   Long duration\n",
        "-   Not always possible\n",
        "-   External validity\n",
        ":::\n",
        "\n",
        "::: {.column width=\"40%\"}\n",
        "<img src=\"assets/randomisation.png\" alt=\"the gold standard for causal effects\" width=\"500\" height=\"600\"/>\n",
        ":::\n",
        ":::\n",
        "\n",
        "## What is Real world Data\n",
        "\n",
        "-   FDA definition “healthcare information derived from multiple sources outside of typical clinical research settings, including *electronic medical records (EMRs)*, *claims and billing data*, *product and disease registries*, and data gathered by *personal devices and health applications*”\n",
        "\n",
        "-   Offers a chance to identify and address gaps in clinical trial evidence\n",
        "\n",
        "## Real World Data\n",
        "\n",
        "- **EMR** (structured and unstructured clinical data reports, imaging, pathology, detailed treatment information)\n",
        "-   **State-wide administrative datasets**\n",
        "    -   Eg NSW Admitted Patient Data collection (Patient admission and discharge date, diagnostic codes, procedures), Emergency Department Data Collection\n",
        "    -   not designed for research\n",
        "    -   important clinical details (eg performance status, comorbidity, data on treatment including rational as well as key pathological features) are frequently poorly documented\n",
        "\n",
        "## Real World Data (ctd)\n",
        "\n",
        "-   **Cancer registries**\n",
        "    -   Richer data sets\n",
        "    -   state-level registries only offer a core minimum dataset, have missing data, completeness of variables and timelines\n",
        "    -   multi-disciplinary,Multi-site national/international registries: more granular level data\n",
        "-   **Linked data sets**\n",
        "\n",
        "## Limitations of Real World Data\n",
        "\n",
        "1.  Data availability and quality\n",
        "2.  Confounding due to no randomisation\n",
        "\n",
        "## Observational data and the C-Word {background-color=#522E91}\n",
        "\n",
        "\" Dear author: Your observational study cannot prove causation. Please replace all references to causal effects by references to associations.\"\n",
        "\n",
        "![](assets/c-word.png)\n",
        "\n",
        "## The Target Trial framework\n",
        "\n",
        "Plan analysis as though data are from a **hypothetical trial**:\n",
        "\n",
        "-   Eligibility criteria\n",
        "-   Time zero\n",
        "-   Treatment strategy clear definition\\\n",
        "-   Assignment procedure\\\n",
        "-   Follow-up period\n",
        "-   Outcome\n",
        "-   Causal contrast (eg ITT effect)\n",
        "-   Analysis plan\n",
        "\n",
        "## Example  {.alt-slide}\n",
        "\n",
        "```{css, echo =FALSE}\n",
        ".alt-slide,\n",
        ".alt-slide h2 {\n",
        "color: #FFFFFF;\n",
        "}\n",
        "```\n",
        "\n",
        "\n",
        "\n",
        "![Miguel A. Hernán, James M. Robins, Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available, American Journal of Epidemiology, Volume 183, Issue 8, 15 April 2016, Pages 758–764](assets/target-trial.png)\n",
        "\n",
        "## Minimising the effect of confounders\n",
        "\n",
        "-   DAGs are useful tool for considering confounders\n",
        "-   “Draw your assumptions before your conclusions”\n",
        "-   forces the research team to carefully think through the confounding variables and their interrelationships\n",
        "\n",
        "## Example: bevacizumab added to paclitaxel in HER2-negative MBC \n",
        "\n",
        "![Antoine A et al. Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort. J Natl Cancer Inst. 2023 Aug 8;115(8):971-980.](assets/DAG.png) \n",
        "\n",
        "## Propensity Matching\n",
        "\n",
        "-   create a “matched population” where the treated and untreated are exchangeable (similar in all other characteristics)\n",
        "\n",
        "-   Propensity scores allow is to determine similarity\n",
        "\n",
        "-   Propensity score is prob of treatment conditional on confounders\n",
        "\n",
        "-   For each treated individual find a untreated individual with a similar propensity score\n",
        "\n",
        "## How well did we achieve ballance\n",
        "\n",
        "::: columns\n",
        "::: {.column width=\"50%\"}\n",
        "![](assets/ballance_overlap.png)\n",
        ":::\n",
        "\n",
        "::: {.column width=\"50%\"}\n",
        "![](assets/ballance_love_plot.png)\n",
        ":::\n",
        ":::\n",
        "\n",
        "## What about umeasured confounders??\n",
        "\n",
        "-   Should perform a sensitivity analysis\n",
        "\n",
        "-   How robust are the results/conclusions to possible un-measured confounders\n",
        "\n",
        "-   The E-value - How big a relative risk (between exposure and confounder) would need be to nullify an effect\n",
        "\n",
        "-   If bigger than any of the measured ones then that means unlikely\n",
        "\n",
        "-   If small then casts doubt on the results\n",
        "\n",
        "## Conclusions\n",
        "\n",
        "-   We can talk about causal effects from real world data\n",
        "-   There are many great local resources\n",
        "-   Should use the target trial framework\n",
        "-   More advanced methods for controlling confounders\n",
        "-   Need sensitivity analyses\n",
        "\n",
        "##  {background-image=\"questions.png\" background-size=\"cover\"}"
      ],
      "id": "4b6e470f"
    }
  ],
  "metadata": {
    "kernelspec": {
      "display_name": "Python 3",
      "language": "python",
      "name": "python3"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}